List of Excipients in API lenvatinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing lenvatinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib | 62856-704 | CALCIUM CARBONATE | 2036-02-26 |
| Eisai Inc | LENVIMA | lenvatinib | 62856-704 | CELLULOSE, MICROCRYSTALLINE | 2036-02-26 |
| Eisai Inc | LENVIMA | lenvatinib | 62856-704 | FERRIC OXIDE RED | 2036-02-26 |
| Eisai Inc | LENVIMA | lenvatinib | 62856-704 | FERRIC OXIDE YELLOW | 2036-02-26 |
| Eisai Inc | LENVIMA | lenvatinib | 62856-704 | FERROSOFERRIC OXIDE | 2036-02-26 |
| Eisai Inc | LENVIMA | lenvatinib | 62856-704 | HYDROXYPROPYL CELLULOSE | 2036-02-26 |
| Eisai Inc | LENVIMA | lenvatinib | 62856-704 | HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED | 2036-02-26 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for lenvatinib
Excipient focus: CALCIUM CARBONATE
lenvatinib drug variants containing CALCIUM CARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing CALCIUM CARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
lenvatinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
lenvatinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
lenvatinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
lenvatinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
lenvatinib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
lenvatinib drug variants containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
lenvatinib drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
lenvatinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM HYDROXIDE
lenvatinib drug variants containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
lenvatinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
lenvatinib drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
lenvatinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
lenvatinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Eisai Inc | lenvatinib | 62856-704 |
| Eisai Inc | lenvatinib | 62856-710 |
| >Company | >Ingredient | >NDC |
lenvatinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch